Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray

Modern Pathology

Volumn 17, Issue 10, 2004, Pages 1217-1222

  Lin, Pei ^a,c   Mahdavy, Mustafa ^a   Zhan, Fenghuang ^b   Zhang, Hua Zhong ^c   Katz, Ruth L ^c   Shaughnessy, John D ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Lambert Lab of Myeloma Genetics   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Affymetrix microarray; CD20; Multiple myeloma; PAX5; PRDM1

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD20 ANTIGEN; PROTEIN; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PAX5 GENE; PLASMA CELL; PRDM1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD20; B-CELL-SPECIFIC ACTIVATOR PROTEIN; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDE PROBES; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 4744354726     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800169     Document Type: Article

References (20)

1. Hagman J, Wheat W, Fitzsimmons D, et al. Pax-5/ BSAP: regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immunol 2000;245:169-194.
2. Lin KI, Angelin-Duclos C, Kuo TC, et al. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol 2002;22:4771-4780.
3. Maier H, Hagman J. Roles of EBF and Pax-5 in B lineage commitment and development. Semin Immunol 2002;14:415-422.
4. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003;19:607-620.
5. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
6. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121-131.
7. Grogan TM, Van Camp B, Kyle RA, et al. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
8. Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 1982;51:361-375.
9. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997;15:2659-2666.
10. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488.
11. Zent CS, Zhan F, Schichman SA, et al. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res 2003;27:765-774.
12. Zwollo P, Arrieta H, Ede K, et al. The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem 1997;272:10160.
13. Kehrl JH, Riva A, Wilson GL, et al. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994;15:432-436.
14. Angelin-Duclos C, Cattoretti G, Lin KI, et al. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000;165:5462-5471.
15. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003;102:1070-1071.
16. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032-1037.
17. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62.
18. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and Oct-2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol 2002;116:429-435.
19. Borson ND, Lacy MQ, Wettstein PJ. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 2002;100:4629-4639.
20. Gyory I, Fejer G, Ghosh N, et al. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol 2003;170:3125-3133.